Investigators implanted intracranial electrodes across the cortico-striato-limbic network in three individuals with OCD to obtain direct electrophysiologic measures before delivering therapeutic stimulation. The report describes recordings made across multiple days and links those neural signals to symptom state and subsequent responses to stimulation. The cohort size was small and the source did not report additional demographic or detailed methodological parameters beyond the implantation and recording strategy.
Data indicated that prefrontal gamma-band activity distinguished high- from low-symptom OCD states reproducibly across recording days. The effect was most prominent in the OFC. Investigators reported that this gamma signal reliably tracked symptom fluctuations within subjects, allowing a within-patient electrophysiologic marker of symptomatic state to emerge from the recordings. The authors did not provide additional population-level statistics in the abstract; full analytical details are available in the preprint and supplementary material.
Acute stimulation of the ventral capsule/ventral striatum produced symptomatic relief in the study participants. In one patient, the team observed a significant shift in the OFC gamma signal coincident with symptom improvement. The manuscript links the immediate clinical effect of stimulation to modulation of prefrontal electrophysiology, although it did not report comprehensive stimulation parameters in the abstract. The authors noted that acute symptom relief could be tracked alongside neural signal changes in at least one individual.
Investigators defined patient-specific OCD subnetworks by mapping effective connectivity from the therapeutic stimulation sites to prefrontal regions. Each participant’s stimulation site showed distinct connectivity patterns, and those effective connections delineated three individualized subnetworks. The study team used those subnetworks to relate baseline network organization to the likelihood of clinical benefit from DBS. The preprint describes these as personalized, subnetwork-level biomarkers rather than as a single universal target.
Baseline strength of the nucleus accumbens/ventral pallidum-OFC subnetwork predicted both acute and longer-term response to DBS in this dataset. Investigators reported that individuals with stronger baseline coupling along this pathway were more likely to experience symptomatic benefit from stimulation. The finding was presented as a within-study predictor derived from the three implanted participants; the source did not provide broader validation in an independent cohort within the abstract.
The authors used imaging-based modeling of current propagation from ventral capsule stimulation to the OFC and found that modeled spread tracked acute clinical response. This suggests that, in principle, imaging-derived estimates of current flow could approximate the electrophysiologic prediction of response. The abstract states that imaging-based models may allow prediction without intracranial recordings, but the source did not claim imaging alone fully replaces direct electrophysiology, and it did not report detailed modeling parameters in the abstract.
The study is registered under ClinicalTrials.gov identifier NCT05623306. De-identified data and analysis code are available on GitHub at the repository listed in the preprint. The University of Pennsylvania IRB provided ethical approval for the research, and the authors confirmed that participant consent and appropriate approvals were obtained. Competing interests and funding sources are declared in the preprint.
This report is a medRxiv preprint and has not been peer reviewed. The study cohort comprised three individuals, which the authors acknowledged by reporting the sample size; generalizability beyond these participants remains untested in larger samples. The source did not specify detailed stimulation settings in the abstract, nor did it provide population-level validation of the proposed predictive subnetwork biomarkers. Whether the observed OFC gamma marker and the nucleus accumbens/ventral pallidum-OFC subnetwork prediction will replicate across broader, more diverse clinical populations—or across different stimulation targets and programming strategies—remains an open question. Future work should test these patient-specific network biomarkers in larger, prospectively enrolled cohorts and report standardized stimulation parameters and statistical metrics to enable translation from preprint to clinical practice.